Zevalin Y-90 Good as Frontline Therapy in Advanced Follicular Lymphoma

The results of an international, multicenter phase II trial evaluating the efficacy and toxicity of fractionated 90Y-ibritumomab tiutetan (otherwise known as Zevalin) for patients with advanced follicular lymphoma indicate that the radioimmunotherapy (RIT) is an effective frontline therapy for these patients.

Y-90 Zevalin is a very convenient and effective form of therapy for lymphoma patients compared to traditional combination chemotherapy. Currently, Y-90 Zevalin is approved for the treatment of recurring, low-grade or follicular B-cell non-Hodgkin's lymphoma following the failure of at least one other treatment regimen, and for the treatment of newly diagnosed follicular lymphoma after a response to other frontline therapy.

This study is likely attempting to pave the way for Y-90 Zevalin to be approved as a frontline therapy in advanced stage follicular lymphoma.

Administering treatment

The study, by Tim M. Illidge, University of Manchester, Manchester Academic Health Sciences Centre, Wilmslow Road, Manchester U.K. and colleagues, recruited 74 patients with a median age of 61 years (ranging from age 28 to 80), 78 percent of whom were diagnosed with stage III-IV disease. Of these patients, 32 percent were considered intermediate, and 44 percent were considered high-risk according to the FLIPI (follicular lymphoma international prognostic index).

Patients were treated with two doses of 90Y-IT administered eight to 12 weeks apart. Those patients found to have at least 20 percent infiltration of bone marrow were given weekly infusions of rituximab for four weeks and then received RIT only if another check of their bone marrow revealed that infiltration had fallen below 20 percent.

This phase II trial's primary end point was an end to treatment response in the intention-to-treat population. Secondary objectives were safety and progression-free survival (PFS).

Examining response rates

After the study, researchers found the following results:

  • Initial overall response rate (ORR): 94.4 percent (68 of 72 patients)
  • Combined complete response (CR/CRu): 58.3 percent (42 of 72 patients). Nine patients subsequently improved response making an ORR of 95.8 percent (69 of 72 patients) and CR/CRu of 69.4 percent (50 of 72 patients).

After a follow-up, researchers found::

  • At a median follow-up of 3.1 years, the estimated three-year PFS is 58 percent
  • Treatment-free survival is 66 percent
  • Overall survival is 95 percent
  • Median PFS is 40.2 months. Thirty patients have experienced disease progression and 24 have required further treatment.

These findings were first presented at the ASH 2011 conference. The researchers are now reporting them in the Journal of Clinical Oncology.

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...